Agalsidase Alfa

@article{Keating2012AgalsidaseA,
  title={Agalsidase Alfa},
  author={Gillian M. Keating},
  journal={BioDrugs},
  year={2012},
  volume={26},
  pages={335-354}
}
The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase A; intravenous agalsidase alfa 0.2 mg/kg every other week is indicated for the long-term treatment of patients with confirmed Fabry disease. This article reviews the efficacy and tolerability of agalsidase alfa in patients with Fabry disease, as well as summarizing its pharmacologic properties. Agalsidase alfa had beneficial effects in adult men with Fabry disease… CONTINUE READING